Sun Pharma Q4 net sales rise 35%
The company has earned net profit of INR4.43bn, resulting into a net margin of 30%. The company has posted net sales of INR57.21bn for the financial year ended
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
The agreement covers kinetoplastid diseases (leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis, and schistosomiasis diseases. Under the